In a Phase I study of 59 patients, 50 of which had ALK-positive NSCLC, of which 37 of these had received critzotinib therapy and 26 of which had progressed on this therapy, 81% of this group (21/26) responded to > 400 mg/day LDK378 [139]. This evidence concerns the gene ALK and non-small cell lung carcinoma.